Coronaviruses have been reported previously due to their association with the severe acute
respiratory syndrome (SARS). After SARS, these viruses were known to be causing Middle …

Abstract SARS-CoV-2 nsp13 helicase is an essential enzyme for viral replication and a
promising target for antiviral drug development. This study compares the double-stranded …

SARS-CoV-2 infection is still spreading worldwide, and new antiviral therapies are an urgent
need to complement the approved vaccine preparations. SARS-CoV-2 nps13 helicase is a …

SARS-CoV-2, also referred to as severe acute respiratory syndrome coronavirus 2, is the
virus responsible for causing COVID-19, an infectious disease that emerged in Wuhan …

Abstract Non-Structural Protein 6 (NSP6) has a protecting role for SARS-CoV-2 replication
by inhibiting the expansion of autophagosomes inside the cell. NSP6 is involved in the …

Background: SARS-CoV-2 emerged in late 2019 and caused COVID-19. Patients treated
with Zyesami were found to have a 3-fold decrease in respiratory failure and improved …

The emergence of fast-spreading SARS-CoV-2 mutants has sparked a new phase of COVID-
19 pandemic. There is a dire necessity for antivirals targeting highly conserved genomic …

The regular reappearance of coronavirus (CoV) outbreaks over the past 20 years has
caused significant health consequences and financial burdens worldwide. The most recent …

Among the different drug targets of SARS-CoV-2, a multi-domain protein known as NSP3 is
a critical element of the translational and replication machinery. The macrodomain-I, in …

Nanobodies are emerging as critical tools for drug design. Several have been recently
created to serve as inhibitors of SARS-Cov-2 entry in the host cell by targeting surface …